TIMOPTOL 0.5 Base %w/v Eye Drops Solution Irland - engelsk - HPRA (Health Products Regulatory Authority)

timoptol 0.5 base %w/v eye drops solution

merck sharp & dohme ireland (human health) limited - timolol maleate - eye drops solution - 0.5 base %w/v

TIMOPTOL UNIT DOSE 0.25 %w/v Eye Drops Solution Irland - engelsk - HPRA (Health Products Regulatory Authority)

timoptol unit dose 0.25 %w/v eye drops solution

merck sharp & dohme ireland (human health) limited - timolol maleate - eye drops solution - 0.25 %w/v

TIMOPTOL UNIT DOSE 0.5 %w/v Eye Drops Solution Irland - engelsk - HPRA (Health Products Regulatory Authority)

timoptol unit dose 0.5 %w/v eye drops solution

merck sharp & dohme ireland (human health) limited - timolol maleate - eye drops solution - 0.5 %w/v

TIMOPTOL OPHTHALMIC SOLUTION 0.5% Singapore - engelsk - HSA (Health Sciences Authority)

timoptol ophthalmic solution 0.5%

santen pharmaceutical asia pte. ltd. - timolol maleate 6.83 mg eqv timolol - solution - 0.50% - timolol maleate 6.83 mg eqv timolol 5.00 mg/ml

Timoptol 0.25% w/v eye drops, solution Irland - engelsk - HPRA (Health Products Regulatory Authority)

timoptol 0.25% w/v eye drops, solution

santen oy - timolol base - eye drops, solution - 0.25 percent weight/volume - beta blocking agents1); timolol - it is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions including the following: patients with ocular hypertension; patients with chronic open-angle glaucoma including aphakic patients; some patients with secondary glaucoma.

Timoptol 0.5% w/v eye drops, solution Irland - engelsk - HPRA (Health Products Regulatory Authority)

timoptol 0.5% w/v eye drops, solution

santen oy - timolol base - eye drops, solution - 0.5 percent weight/volume - beta blocking agents1); timolol - it is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions including the following: patients with ocular hypertension; patients with chronic open-angle glaucoma including aphakic patients; some patients with secondary glaucoma.